Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference

PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) — Kriya Therapeutics, Inc. (“Kriya”), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced that Shankar Ramaswamy, M.D., Co-Founder and CEO, will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th, at 9:00 AM PT in San Francisco, California.

About Kriya Therapeutics
Our mission is to revolutionize medicine, with the ultimate goal of eliminating human suffering and enabling people to live without the burden of disease. Kriya is a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million, which will be used to advance a broad pipeline of gene therapies for ophthalmology, neurology and metabolic disease. For more information, please visit www.kriyatx.com and follow us on LinkedIn and X (Formerly Twitter).

CONTACT: Kriya Media Contact:
Kelli Perkins
kelli@redhousecomms.com

Staff

Recent Posts

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

5 hours ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

5 hours ago